Additionally, we will provide resources for managing side effects, nutrition habits, and exercise
This article does not provide dosage recommendations, topical-use instructions, injection guidance, preparation procedures, timing schedules, combination protocols, safety advice, or human-use directions
Palfi S, Gurruchaga JM, Ralph GS, et al
You can read the full article atYou can read the full article at Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial Due to increased obesity and inactivity rates, type 2 diabetes (T2D) is a complex, multifaceted disease with a rising prevalence rate
Ideal Candidates Tirzepatide is suitable for adults with a body mass index (BMI) of 30 or higher, or those with a BMI of 27 or higher who have at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia